Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) managing director Dr Richard Hopkins has shown his faith in the company’s therapeutic medicinal cannabis strategy by participating in a placement that raised A$8.75 million. On August 11, 2020, Hopkins acquired 1 million shares at A$0.05 per share after his participation in the placement was approved by shareholders on July 21, 2020. Zelira Therapeutics MD…
Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) is one of three companies set to present at Proactive’s medical cannabis focussed webinar on Tuesday, August 11, along with MGC Pharmaceuticals Ltd (ASX:MXC) and Southern Cannabis Holdings. The Proactive CEO Investor Sessions is an online variant of the popular conference format the media company has run for over a decade and enables communication between…
If you’ve been living with chronic pain, you’ll know how hard it can be to perform simple everyday tasks like getting out of bed in the morning. The good news is Aussie researchers may have found a solution — and no, it doesn’t involve loading up on large doses of drugs. A new study has found medicinal cannabis can safely…
Cannabis medicines validation specialist Zelira Therapeutics Ltd (ASX:ZLD) has received the final clinical report for its Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment. The phase 1 dose-escalation trial was designed to assess the safety of Zelira’s cannabis formulation (ZTL- 103) in chronic pain patients already on long-term high-dose opioid treatment. TechInvest – Zelira…
Zelira Therapeutics (ZLD) has confirmed its phase one dose-escalation trial of ZTL-103 has successfully met its primary and secondary endpoints for safety and efficacy. The study was conducted at the St Vincent’s Hospital in Melbourne, as well as Emerald Clinics (EMD) in Perth. The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated
Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCMKTS:ZLDAF) final clinical report for a Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment shows that the primary and secondary endpoints for safety and efficacy were met. Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
Zelira Therapeutics (ASX:ZLD) has completed another medicinal cannabis trial and passed with flying colours. This time it was a Phase 1 dose escalation study assessing the safety of its cannabis formulation in chronic pain patients using opioids as a treatment. The study met its primary end points in being well tolerated and having no serious adverse effects. Pot stock Zelira…
Zelira Therapeutics LTD, a therapeutic medicinal cannabis company, is developing clinically validated cannabis products for the treatment of various medical conditions. Chairman of Zelira, Osagie Imasogie, will be presenting at the event, along with Managing Director ex USA, Dr. Richard Hopkins. Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More
Q&A with Osagie Imasogie Chairman, Zelira Therapeutics Zelira Therapeutics Ltd (Zelira; the Company) is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest growing cannabis markets. The Company is focused on developing clinically validated branded cannabis products for the treatment of a variety of medical conditions. Product development programs are underway targeting specific conditions…
Zelira says its 23-patient, phase Ib/IIa trial of marijuana-derived ZLT-101 has shown safety and statistical significance for reduction of chronic insomnia. Zelira said that the randomised, double-blind, cross-over trial treated patients for 14 nights with ZTL-101 and 14 nights of placebo, separated by a one-week washout period at the University of Western Australia Centre for Sleep Science. Biotech Daily –…